15 results on '"Ji, A.-C."'
Search Results
2. Accurate determination of an immunosuppressant in stented swine tissues with LC–MS/MS
- Author
-
Zhang, Jun, Reimer, Micheal T., Ji, Qin C., Chang, Min S., El-Shourbagy, Tawakol A., Burke, Sandra, and Schwartz, Lewis
- Published
- 2007
- Full Text
- View/download PDF
3. A validated enantioselective LC–MS/MS assay for quantification of a major chiral metabolite of an achiral 11-β-hydroxysteroid-dehydrogenase 1 inhibitor in human plasma: Application to a clinical pharmacokinetic study.
- Author
-
Furlong, Michael T., Ji, Qin C., Iacono, Lisa, Dang, Oanh, Noren, Marzena, Bruce, John, Aubry, Anne-Françoise, and Arnold, Mark E.
- Subjects
- *
ENANTIOSELECTIVE catalysis , *LIQUID chromatography-mass spectrometry , *CHIRALITY , *METABOLITES , *HYDROXYSTEROID dehydrogenases , *ENZYME inhibitors , *BLOOD plasma , *PHARMACOKINETICS - Abstract
BMS-823778 is a potent 11-β-hydroxysteroid-dehydrogenase 1 (11βHSD-1) inhibitor and a potential therapeutic agent for type 2 diabetes mellitus (T2DM). A high performance liquid chromatography-tandem mass spectrometry (LC–MS/MS) assay was developed and validated to enable reliable separation and quantification of both enantiomers of a chiral hydroxy metabolite (BMT-094817) in human plasma. Following liquid–liquid extraction in a 96-well plate format, chromatographic separation of the metabolite enantiomers was achieved by isocratic elution on a Chiralpak IA-3 column. Chromatographic conditions were optimized to ensure separation of both metabolite enantiomers. Metabolite enantiomers and stable isotope-labeled (SIL) internal standards were detected by positive ion electrospray tandem mass spectrometry. The LC–MS/MS assay was validated over a concentration range of 0.200–200 ng/mL. Intra- and inter-assay precision values for replicate quality control samples were less than 9.9% for both enantiomers during the assay validation. Mean quality control accuracy values were within ±7.3%. Assay recoveries were high (>75%) and consistent across the assay range. The metabolite enantiomers were stable in human blood for 2 h on ice. The analytes were also stable in human plasma for 25 h at room temperature, 34 days at −20 °C and −70 °C, and following five freeze-thaw cycles. No interconversion of the metabolite enantiomers was detected under any bioanalytical stress conditions, from blood collection/processing through extracted sample storage. The validated assay was successfully applied to the quantification of both metabolite enantiomers in human plasma in support of a human pharmacokinetic study. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
4. Liquid chromatography coupled with tandem mass spectrometry for the bioanalysis of proteins in drug development: Practical considerations in assay development and validation
- Author
-
Liu, Guowen, Ji, Qin C., Dodge, Robert, Sun, Huadong, Shuster, David, Zhao, Qihong, and Arnold, Mark
- Subjects
- *
TANDEM mass spectrometry , *LIQUID chromatography , *DRUG development , *PROTEIN fractionation , *PROTEIN drugs , *PHARMACOKINETICS , *WORKFLOW , *LIGAND binding (Biochemistry) , *TOXICOLOGY - Abstract
Abstract: In recent years, there has been increasing interest in using LC–MS/MS to measure protein drugs (biotherapeutics) in plasma/serum to support pharmacokinetic/toxicokinetic (PK/TK) studies. A number of strategies have been proposed to quantify different types of protein drug candidates in biological matrices. However, the application of LC–MS/MS in biotherapeutics is still very limited in regulated bioanalysis due to practical challenges. In this manuscript, we propose a “data-dependent” approach for the LC–MS/MS support of protein drug candidates, focusing on operational aspects. We have developed and validated a fast, simple and reliable LC–MS/MS method to quantify a protein drug candidate in mouse serum. This method can fit into our current workflow for routine small molecule LC–MS/MS assays with an overall sample preparation time of less than two hours. The method has been demonstrated to be accurate, precise and rugged, and it has been successfully applied to analyze samples from toxicology studies. The results were verified using a ligand binding assay and tested by standard-addition sample reanalysis. In addition, general recommendations for developing and validating an LC–MS/MS assay based on surrogate peptide(s) of protein drug candidates are also proposed for regulated bioanalysis. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
5. A sample preparation process for LC–MS/MS analysis of total protein drug concentrations in monkey plasma samples with antibody
- Author
-
Ji, Qin C., Rodila, Ramona, and El-Shourbagy, Tawakol A.
- Subjects
- *
PROTEINS , *ENZYME-linked immunosorbent assay , *IMMUNOGLOBULINS , *ANTIGENS , *MASS spectrometry - Abstract
Abstract: The determination of protein concentrations in plasma samples often provides essential information in biomedical research, clinical diagnostics, and pharmaceutical discovery and development. Binding assays such as ELISA determine meaningful free analyte concentrations by using specific antigen or antibody reagents. Concurrently, mass spectrometric technology is becoming a promising complementary method to traditional binding assays. Mass spectrometric assays generally provide measurements of the total protein analyte concentration. However, it was found that antibodies may bind strongly with the protein analyte such that total concentrations cannot be determined. Thus, a sample preparation process was developed which included a novel “denaturing” step to dissociate binding between antibodies and the protein analyte prior to solid phase extraction of plasma samples and LC–MS/MS analysis. In so doing, the total protein analyte concentrations can be obtained. This sample preparation process was further studied by LC–MS analysis with a full mass range scan. It was found that the protein of interest and other plasma peptides were pre-concentrated, while plasma albumin was depleted in the extracts. This capability of the sample preparation process could provide additional advantages in proteomic research for biomarker discovery and validation. The performance of the assay with the novel denaturing step was further evaluated. The linear dynamic range was between 100.9ng/mL and 53920.0ng/mL with a coefficient of determination (r 2) ranging from 0.9979 and 0.9997. For LLOQ and ULOQ samples, the inter-assay CV was 12.6% and 2.7% and inter-assay mean accuracies were 103.7% and 99.5% of theoretical concentrations, respectively. For QC samples, the inter-assay CV was between 2.1% and 4.9%, and inter-assay mean accuracies were between 104.1% and 110.0% of theoretical concentrations. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
6. Overcoming the stability, solubility and extraction challenges in reversed-phase UHPLC–MS/MS bioanalysis of a phosphate drug and its prodrug in blood lysate.
- Author
-
Yuan, Long, Basdeo, Shenita, and Ji, Qin C.
- Subjects
- *
PRODRUGS , *EXTRACTION (Chemistry) , *MATRIX effect , *KINASE inhibitors , *STABLE isotopes , *LABORATORY rats - Abstract
BMS-986104 is a S1P 1 R modulator drug candidate under development and has been evaluated in Phase I clinical trials. BMS-986104 functions as a prodrug and undergoes enzymatic transformations in vivo to form the pharmacologically active phosphate drug, BMS-986104-P. Here, we report approaches to overcome the stability, solubility and extraction challenges in developing a sensitive, accurate and rugged LC–MS/MS method for the simultaneous quantification of the phosphate drug and its prodrug in blood lysate. An effective stabilization strategy using a cocktail of phosphatase and kinase inhibitors was developed to ensure the stability of both analytes during sample collection, storage, and processing. A combination of surfactant (CHAPS) and weak base (Tris) was found to be able to effectively improve the solubilization of the phosphate drug. The blood lysate samples were extracted by protein precipitation followed by solid-phase extraction using an Oasis HLB 96-well SPE plate. The method achieved acceptable matrix effect and recovery for the two analytes that have very different chemical properties. Stable-isotope labeled D6-BMS-986104 and D13-BMS-986104-P were utilized as the internal standards. Chromatographic separation was achieved using isocratic conditions on an Acquity UPLC BEH C18 analytical column. The two analytes and their internal standards were detected by positive ion electrospray tandem mass spectrometry. The calibration curves, which ranged from 2.00 to 2000 ng/mL for BMS-986104 and 4.00 to 4000 ng/mL for BMS-986104-P, were fitted to a 1/x2 weighted linear regression model. The intra-assay precision was within ±5.0% CV, inter-assay precision was within ±4.9% CV, and the assay accuracy was within ±5.8% of the nominal values for both analytes in rat blood lysate. The method was validated and successfully applied to support multiple pre-clinical toxicity studies. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
7. Development and validation of a liquid chromatography–tandem mass spectrometry assay for the simultaneous quantitation of prednisolone and dipyridamole in human plasma and its application in a pharmacokinetic study
- Author
-
Chen, Mei, Granvil, Camille, Ji, Qin C., Zhang, Zhi-Yi, Padval, Mahesh V., and Kansra, Vikram V.
- Subjects
- *
LIQUID chromatography , *TANDEM mass spectrometry , *ANALYTICAL biochemistry , *ANTITHROMBINS , *OPHTHALMIC drugs , *BLOOD plasma , *PHARMACOKINETICS , *HIGH throughput screening (Drug development) - Abstract
Abstract: We have developed and validated an accurate, sensitive, and robust LC–MS/MS method that determines the concentration of CRx-102 (the combination of prednisolone and dipyridamole) in human plasma. In this method, prednisolone, dipyridamole, and the combined internal standards (IS) prednisolone-d6 (IS for prednisolone) and dipyridamole-d20 (IS for dipyridamole) were extracted from 100μL human EDTA plasma using methylbutyl ether. Calibration curves were linear over a concentration range of 0.4–200ng/mL for prednisolone and 5–3000ng/mL for dipyridamole. The analytes were quantitatively determined using tandem mass spectrometry operated in positive electrospray ionization in a multiple reaction monitoring (MRM) mode. This validated method has been used successfully in clinical pharmacokinetic studies of CRx-102 in healthy volunteers. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
8. Enantioselective determination of alprenolol in human plasma by liquid chromatography with tandem mass spectrometry using cellobiohydrolase chiral stationary phases
- Author
-
Jiang, Hongliang, Jiang, Xiangyu, and Ji, Qin C.
- Subjects
- *
ALPRENOLOL , *LIQUID chromatography , *CELLULOSE 1,4-beta-cellobiosidase , *ENANTIOSELECTIVE catalysis , *TANDEM mass spectrometry , *EXTRACTION techniques , *STANDARD deviations , *BLOOD testing - Abstract
Abstract: A fast, sensitive, and enantioselective LC–MS/MS bioanalytical method was developed and validated for the direct determination of individual alprenolol enantiomers in human plasma using cellobiohydrolase (CBH) chiral stationary phases (CSP) along with supported liquid extraction (SLE) procedures. Complete baseline separation of enantiomeric alprenolol was achieved within 2min in reversed phase chromatography at 0.9ml/min. SLE in a 96-well plate format was used for sample extraction. The method validation was conducted over the curve range of 0.500–500ng/ml for each alprenolol enantiomer using 0.0500ml of plasma sample. The intra- and inter-day precision and accuracy of the quality control samples at low, medium, and high concentration levels showed ≤7.3% relative standard deviation (RSD) and −6.2 to 8.0% relative error (RE) for both alprenolol enantiomers. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
9. A convenient strategy to overcome interference in LC-MS/MS analysis: Application in a microdose absolute bioavailability study.
- Author
-
Yuan, Long, Huang, Christine, Liu-Kreyche, Peggy, Voronin, Kimberly, Fancher, R. Marcus, Allentoff, Alban, Zheng, Naiyu, Iyer, Ramaswamy, Zhu, Li, Pillutla, Renuka, and Ji, Qin C.
- Subjects
- *
LIQUID chromatography-mass spectrometry , *ACCELERATOR mass spectrometry , *COST effectiveness , *MOLECULAR weights , *IMMUNOASSAY , *ISOTOPES - Abstract
Highlights • A convenient and cost-effective strategy to overcome interference in LC–MS analysis. • This strategy minimizes the number of stable isotope labels used for avoiding interference. • A LC–MS/MS assay utilizing this strategy was developed for BMS-986205. • The developed assay was successfully applied to a dog absolute bioavailability study. • The strategy can also be applied to the selection of internal standards. Abstract Stable isotope labeled (SIL) compounds have been commonly used as internal standards (IS) to ensure the accuracy and quality of liquid chromatography–mass spectrometry (LC–MS) bioanalytical assays. Recently, the application of SIL drugs and LC–MS assays to microdose absolute bioavailability (BA) studies has gained increasing attention. This approach can provide significant cost and time saving, and higher data quality compared to the accelerator mass spectrometry (AMS)-based method, since it avoids the use of radioactive drug, high-cost AMS instrumentation and complex measurement processes. It also eliminates potential metabolite interference with AMS-based assay. However, one major challenge in the application of this approach is the potential interference between the unlabeled drug, the microdose SIL drug, and the SIL-IS during LC–MS analysis. Here we report a convenient and cost-effective strategy to overcome the interference by monitoring the isotopic ion (instead of the commonly used monoisotopic ion) of the interfered compound in MS analysis. For the BMS-986205 absolute BA case study presented, significant interference was observed from the microdose IV drug [13C 7, 15N]-BMS-986205 to its SIL-IS, [13C 7, 15N, D 3 ]-BMS-986205, since the difference of nominal molecular mass between the two compounds is only 3 mu, and there is a Cl atom in the molecules. By applying this strategy (monitoring the 37Cl ion for the analysis of the IS), a 90-fold reduction of interference was achieved, which allowed the use of a synthetically accessible SIL compound and enabled the fast progress of the absolute BA study. This strategy minimizes the number of stable isotope labels used for avoiding interference, which greatly reduces the difficulty in synthesizing the SIL compounds and generates significant time and cost savings. In addition, this strategy can also be used to reduce the MS response of the analyte, therefore, avoiding the detector saturation issue of LC–MS/MS assay for high concentration BMS-986205. A LC–MS/MS assay utilizing this strategy was successfully developed for the simultaneous analysis of BMS-986205 and [13C 7 , 15N]-BMS-986205 in dog plasma using [13C 7, 15N, D 3 ]-BMS-986205 as the IS. The assay was successfully applied to a microdose absolute BA study of BMS-986205 in dogs. The assay was also validated in human plasma and used to support a human absolute BA study. The same strategy can also be applied to other compounds, including those not containing Cl or other elements with abundant isotopes, or other applications (e.g. selection of internal standard), and the applications were presented. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
10. Investigation of the “true” extraction recovery of analytes from multiple types of tissues and its impact on tissue bioanalysis using two model compounds.
- Author
-
Yuan, Long, Ma, Li, Dillon, Lisa, Fancher, R. Marcus, Sun, Huadong, Zhu, Mingshe, Lehman-McKeeman, Lois, Aubry, Anne-Françoise, and Ji, Qin C.
- Subjects
- *
EXTRACTION (Chemistry) , *CALIBRATION , *LIQUID chromatography-mass spectrometry , *SURFACE active agents , *QUANTITATIVE chemical analysis - Abstract
LC-MS/MS has been widely applied to the quantitative analysis of tissue samples. However, one key remaining issue is that the extraction recovery of analyte from spiked tissue calibration standard and quality control samples (QCs) may not accurately represent the “true” recovery of analyte from incurred tissue samples. This may affect the accuracy of LC-MS/MS tissue bioanalysis. Here, we investigated whether the recovery determined using tissue QCs by LC-MS/MS can accurately represent the “true” recovery from incurred tissue samples using two model compounds: BMS-986104, a S1P 1 receptor modulator drug candidate, and its phosphate metabolite, BMS-986104-P. We first developed a novel acid and surfactant assisted protein precipitation method for the extraction of BMS-986104 and BMS-986104-P from rat tissues, and determined their recoveries using tissue QCs by LC-MS/MS. We then used radioactive incurred samples from rats dosed with 3 H-labeled BMS-986104 to determine the absolute total radioactivity recovery in six different tissues. The recoveries determined using tissue QCs and incurred samples matched with each other very well. The results demonstrated that, in this assay, tissue QCs accurately represented the incurred tissue samples to determine the “true” recovery, and LC-MS/MS assay was accurate for tissue bioanalysis. Another aspect we investigated is how the tissue QCs should be prepared to better represent the incurred tissue samples. We compared two different QC preparation methods (analyte spiked in tissue homogenates or in intact tissues) and demonstrated that the two methods had no significant difference when a good sample preparation was in place. The developed assay showed excellent accuracy and precision, and was successfully applied to the quantitative determination of BMS-986104 and BMS-986104-P in tissues in a rat toxicology study. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
11. A UHPLC–MS/MS bioanalytical assay for the determination of BMS-911543, a JAK2 inhibitor, in human plasma.
- Author
-
Liu, Jane, Yuan, Long, Liu, Guowen, Shen, Jim X., Aubry, Anne-Françoise, Arnold, Mark E., and Ji, Qin C.
- Subjects
- *
BIOLOGICAL assay , *JANUS kinases , *MYELOPROLIFERATIVE neoplasms , *ELECTROSPRAY ionization mass spectrometry , *LIQUID-liquid extraction , *THERAPEUTICS - Abstract
Herein we report a rapid, accurate and robust UHPLC–MS/MS assay for the quantitation of BMS-911453, a Janus kinase 2 inhibitor under clinical development for the treatment of myeloproliferative disorders, in human plasma. A systematic method development approach was used to optimize the mass spectrometry, chromatography, and sample extraction conditions, and to minimize potential bioanalytical risks. The validated method utilizes stable-isotope labeled 13 C 4 -BMS-911543 as the internal standard. Liquid-liquid extraction was used for sample preparation. Chromatographic separation was achieved within 2 min on a Zorbax Extend-C18 column with an isocratic elution. BMS-911543 and its internal standard were detected by positive ion electrospray tandem mass spectrometry. The assay range was from 1 to 500 ng/mL, and the standard curve was fitted with 1/ x 2 weighted linear regression. The intra-assay precision was within 5.0% CV and the inter-assay precision was within 2.6% CV. The inter-assay mean accuracy, expressed as percents of theoretical, was between 99.8% and 102.3%. The assay has high recovery (∼80%) and minimal matrix effect (0.95–1.00). BMS-911543 was stable in human plasma for at least 24 h at room temperature, 90 days at −20 °C, and following three freeze–thaw cycles. The validated method was successfully applied to sample analysis in clinical studies. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
12. Quantification of CLR1401, a novel alkylphosphocholine anticancer agent, in rat plasma by hydrophilic interaction liquid chromatography–tandem mass spectrometric detection
- Author
-
Jiang, Hongliang, Cannon, Michelle J., Banach, Maria, Pinchuk, Anatoly N., Ton, Giangthy N., Scheuerell, Christie, Longino, Marc A., Weichert, Jamey P., Tollefson, Richard, Clarke, William R., Ji, Qin C., and Jiang, Xiangyu
- Subjects
- *
LIQUID-liquid interfaces , *ANTINEOPLASTIC agents , *LABORATORY rats , *LIQUID chromatography , *TANDEM mass spectrometry , *EXTRACTION (Chemistry) , *PHARMACOKINETICS , *STANDARD deviations - Abstract
Abstract: A rapid and specific LC–MS/MS based bioanalytical method was developed and validated for the determination of 18-(p-iodophenyl)octadecyl phosphocholine (CLR1401), a novel phosphocholine drug candidate, in rat plasma. The optimal chromatographic behavior of CLR1401 was achieved on a Kromasil silica column (50mm×3mm, 5μm) under hydrophilic interaction chromatography. The total LC analysis time per injection was 2.8min with a flow rate of 1.5mL/min under gradient elution. Liquid–liquid extraction in a 96-well format using ethyl acetate was developed and applied for method validation and sample analysis. The method validation was conducted over the curve range of 2.00–1000ng/mL using 0.0500mL of plasma sample. The intra- and inter-day precision and accuracy of the quality control samples at low, medium, and high concentration levels showed≤5.9% relative standard deviation (RSD) and −10.8 to −1.4% relative error (RE). The method was successfully applied to determine the toxicokinetics of CLR1401 in rats from three dose groups of 0.4, 4.0, and 10.0mg/kg/day via intravenous administration. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
13. Study of dried blood spots technique for the determination of dextromethorphan and its metabolite dextrorphan in human whole blood by LC–MS/MS
- Author
-
Liang, Xiaorong, Li, Yinghe, Barfield, Matthew, and Ji, Qin C.
- Subjects
- *
DEXTROMETHORPHAN , *BLOOD testing , *METABOLITES , *QUANTITATIVE research , *HIGH performance liquid chromatography , *TANDEM mass spectrometry , *BIOLOGICAL assay - Abstract
Abstract: Dried blood spots (DBSs) technology was evaluated in an assay for the quantitation of dextromethorphan (DM) and its metabolite, dextrorphan (DT), in human whole blood using high performance liquid chromatography with tandem mass spectrometry method (LC–MS/MS). Both the parent drug and metabolite were spiked in the blood matrix and subsequently allowed to dry on a specimen collection card. The dried blood spots were removed using a manual punch and then extracted into methyl tert-butyl ether (MTBE). The organic supernatant was transferred and evaporated and the residue was reconstituted in 20% acetonitrile. The overall method recovery of DM and DT was 87.8% and 95.4%, respectively. The assay was linear over the concentration range of 0.2–200ng/mL for both analytes. Several factors that potentially affect DBS assay quantitation were investigated, such as punch size, DBS sample punch-out location, and the volume of the blood sample pipetted on the specimen collection cards. The study determined that punch size does not affect assay quantitation accuracy. Indeed, a larger punch size increases the sensitivity due to the larger sampled blood spots. Sampling from different location on the specimen collection cards shows no significant variation for both drugs. The study also shows that acceptable results can be achieved with some variation of the sample volume, which allows a simple blood sampling procedure at the test sites. To achieve the similar lower limit of quantitation (LLOQ) as the plasma assay, several blood spots at the same concentration level were stacked together and extracted. Bioanalytical assays using the DBS technique are promising given the advantages of the method over the plasma assay. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
14. Determination of molindone enantiomers in human plasma by high-performance liquid chromatography–tandem mass spectrometry using macrocyclic antibiotic chiral stationary phases
- Author
-
Jiang, Hongliang, Li, Yinghe, Pelzer, Mary, Cannon, Michelle J., Randlett, Christopher, Junga, Heiko, Jiang, Xiangyu, and Ji, Qin C.
- Subjects
- *
CHROMATOGRAPHIC analysis , *MASS spectrometry , *LIQUID chromatography , *HIGH performance liquid chromatography - Abstract
Abstract: A sensitive and selective bioanalytical assay was developed and validated for the determination of enantiomeric molindone in human plasma using high-performance liquid chromatography–tandem mass spectrometry along with supported liquid extraction procedures. The chiral separation was evaluated and optimized on macrocyclic antibiotic type chiral stationary phases (CSPs) based on teicoplanin aglycone (Chirobiotic TAG) in polar organic, polar ionic, and reversed-phase mode chromatography, respectively. Complete baseline separation was achieved on a Chirobiotic TAG column under isocratic condition in reversed-phase chromatography. The method validation was conducted using a Chirobiotic TAG column (100mm×2.1mm) over the curve range 0.100–100ng/ml for each molindone enantiomer using 0.0500ml of plasma sample. The flow rate was 0.8ml/min and the total run time was 9min. Supported liquid extraction in a 96-well plate format was used for sample preparation. Parameters including recovery, matrix effect, linearity, sensitivity, specificity, carryover, precision, accuracy, dilution integrity, and stability were evaluated. The intra- and inter-day precision and accuracy of the quality control samples at low, medium, and high concentration levels were RSD ≤3.4% and relative error (RE) ≤4.2% for molindone enantiomer 1, and RSD ≤2.6% and RE ≤5.0% for molindone enantiomer 2, respectively. This validated method could be used for the determination of individual molindone enantiomer in human plasma samples from clinical studies. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
15. Application of in-sample calibration curve methodology for regulated bioanalysis: Critical considerations in method development, validation and sample analysis.
- Author
-
Yuan, Long, Gu, Huidong, Zeng, Jianing, Pillutla, Renuka C., and Ji, Qin C.
- Subjects
- *
LIQUID chromatography-mass spectrometry , *ISOTOPOLOGUES , *TANDEM mass spectrometry , *CALIBRATION , *CURVES - Abstract
• First application of in-sample calibration curve (ISCC) methodology in regulated bioanalysis. • Proposed method validation procedures/processes for ISCC–LC–MS/MS methods. • Successfully developed and validated an ISCC−LC–MS/MS method for BMS-984478. • Discussed the great potential of ISCC methodology for various quantitative applications. Traditionally, for a liquid chromatography tandem mass spectrometry (LC–MS/MS) bioanalytical assay, an external calibration curve is required to achieve accurate quantitation of an analyte. Recently, a novel in-sample calibration curves (ISCC) methodology that can achieve quick and accurate LC–MS/MS bioanalysis without the use of an external calibration curve was reported. The ISCC methodology utilizes the presence of multiple naturally occurring isotopologues of a stable isotopically labeled analyte to construct an in-sample calibration curve for the quantification. This methodology has great potential in many applications, for example biomarker measurement, quantitative proteomics and clinical diagnosis. Here, we assessed the feasibility of applying this ISCC–LC–MS/MS methodology in regulated bioanalysis using BMS-984478, a drug candidate, as the model compound. We also proposed method validation procedures/processes for this new approach for industry peers' consideration and feedback. A LC–MS/MS method using the ISCC strategy was successfully developed and validated for the quantitative analysis of BMS-984478 in human plasma over the range of 1.33–993.42 ng/mL. The validated ISCC-LC–MS/MS method was compared with a previously validated method using the conventional external calibration curve approach, and the two methods showed equivalent performance. Critical considerations and practical approaches in method development, validation and sample analysis were also discussed. Our work demonstrated that the ISCC–LC–MS/MS methodology is a promising approach for regulated LC–MS/MS bioanalysis. ISCC–LC–MS/MS methodology has its unique advantages and has great potential to be widely applied for various quantitative applications, and may even change the landscape of quantitative analysis. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.